Table 3

Correlations between sCD163, sTWEAK and sCD163/sTWEAK ratio and clinical and laboratory parameters of patients with systemic sclerosis.

Parameter

(number of subjects)

R Spearman (P-value)

sCD163

sTWEAK

sCD163/sTWEAK


Disease duration (89)

-0.09

(P >0.05)

-0.32

P = 0.002

0.23

P = 0.03

Duration of Raynaud's phenomenon (54)

0.14

(P >0.05)

0.11

(P >0.05)

0.03

(P >0.05)

mRSS (82)

0.03

(P >0.05)

-0.08

(P >0.05)

0.13

(P >0.05)

FVC (75)

-0.06

(P >0.05)

-0.22

(P >0.05)

0.09

(P >0.05)

DLCO (53)

-0.09

(P >0.05)

-0.05

(P >0.05)

-0.02

(P >0.05)

PASP (57)

-0.14

(P >0.05)

-0.20

(P >0.05)

0.11

(P >0.05)

ESR (51)

0.15

(P >0.05)

0.07

(P >0.05)

0.04

(P >0.05)


sTWEAK, soluble tumour necrosis factor-like weak inducer of apoptosis; DLCO, diffusing capacity of the lungs for carbon monoxide; ESR, erythrocyte sedimentation rate; FVC, forced vital capacity; mRSS, modified Rodnan skin score; PASP, pulmonary artery systolic pressure.

Kowal-Bielecka et al. Arthritis Research & Therapy 2013 15:R69   doi:10.1186/ar4246

Open Data